CHANGING
frenCH reseArch Network aGaINst Glioblastoma
The CHANGING project aims to better understand the biological and clinical importance of GAMC to develop new clinically relevant biomarkers and innovative therapeutic strategies. To achieve this project, CHANGING will create five work packages (WP):
(i) WP1 will build the national, virtual, interoperable, and multimodal database/biobank on glioblastoma, whose resources will be used by other WPs/projects;
(ii) WP2 will study the biological value of GAMC through multi-omics studies on single cells;
(iii) guided by WP2 data, WP3 will explore the diagnostic and prognostic value of GAMC via methylome profiling and artificial intelligence approaches;
(iv) WP4 will leverage on biological data from WPs 2 and 3 and from other projects to therapeutically modulate GAMC using pharmacological and physical agents; and
(v) in collaboration with patient/caregiver associations, WP5 will study the needs, unnoticed by researchers, of GBM patients to develop innovative tools directly addressing patient concerns in terms of quality of life.
== Image
Project period
-
Main investigator
Ahmed Id Baih, AP-HP
SESSTIM member(s) of the project:
Sponsors:
Institut National du Cancer (INCa)
Partners:
ARTC ; ARTC-Sud ; Amour Amour Amour ; Des Étoiles dans la Mer ; Institut National du Cancer (INCa) ; Assitance Publique des Hôpitaux de Paris (AP-HP) ; Institut du Cerveau (ICM) ; Sorbonne Université (Faculté de Santé) ; Hôpital de la Pitié-Salpêtrière ; Inserm ; Centre National de la Recherche Scientifique (CNRS) ; SiRIC CURAMUS ; Inria ; Hôpitaux Universitaires de Marseille (AP-HM) ; Hospices Civils de Lyon ; Aix-Marseille Université ; Institut Universitaire du Cancer de Toulouse ; Centre Borelli ; Institut Curie
Project website:
https://labrexchanging.fr/
Research topics:
Research question:
Glioblastoma (GBM) is the most frequent and severe cancer of the central nervous system. Despite intensive treatments accompanied by numerous side effects, the prognosis for GBM patients remains poor, with modest progress over the last twenty years, resulting in a 5-year survival rate of less than 5%. The development of new therapeutic strategies is urgent. In the field of immunotherapies, those modulating T lymphocytes have proven disappointing in GBM thus far. Therefore, within the framework of the CHANGING research network/project (frenCH reseArch Network aGaINst Glioblastoma), we propose to investigate the biology and clinical, diagnostic, and therapeutic potential of another, largely predominant, population of immune cells: GBM associated myeloid cells (GAMC).
Method:
The CHANGING network brings together 14 constitutive teams and 39 associated teams spread across the entire national territory. The involved teams are experts in experimental neuro-oncology including single cell/spatial biology, clinical neuro-oncology, bioinformatics, artificial intelligence, immunology, and humanities and social sciences. Four patient/caregiver associations will contribute fully to the governance and research projects of CHANGING. The CHANGING network will also leverage on existing research programs and structured care networks in neuro-oncology, supported by the Institut National du Cancer (PAIR programs, clinical excellence network on glioblastoma GLIOREC, SIRIC, PRT-K, CLIPP, clinical and biological database/biobank BCB glioblastoma, and RENOCLIP-LOC).
Research prospects:
At the end of the CHANGING project, we hope to better understand the significant role of GAMC in the development of GBM and propose an early phase clinical trial.
Results:
Project in the launch phase.
French Research Network of Excellence against Glioblastoma https://labrexchanging.fr/
